Drug intelligence / Profile preview

SO-002D

Development stage: Preclinical
Lead developer: SOICUM
Modality: Small Molecules

Overview

SO-002D is a preclinical-stage small molecule derivative of SO-002 being developed by SOCIUM (SOICUM) for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). It targets TAR DNA-binding protein 43 (TDP-43), a protein whose pathological aggregation is a hallmark of these neurodegenerative diseases. SO-002D is designed as a new compound derivative to optimize the therapeutic profile of the parent drug SO-002.

Targets

TARDBP (TAR DNA-binding protein 43)

Beyond the preview

Go deeper on SO-002D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SO-002D.